

Code	Group	Demographics						
		Gender	Age	Education	Disease duration	MMSE	Current medication	Tone deaf? (Y/N)
			(years)		(raw)			
1	AD	F	49	10	4.8	14	Donepezil 10mg nocte	N
2	AD	M	53	10	3.9	23	Donepezil 10mg nocte	N
3	AD	M	56	16	3.4	28	Rivastigmine 6mg b.d.	N
4	AD	M	60	13	5.1	24	Donepezil 10mg nocte	N
5	AD	F	60	14	6.9	15	Donepezil 10mg nocte	N
6	AD	F	60	17	2.1	27	Donepezil 10mg nocte	N
7	AD	F	62	16	5.0	18	Donepezil 10mg nocte	N
8	AD	F	62	16	8.0	26	Donepezil 10mg nocte	N
9	AD	F	63	10	4.3	23	Donepezil 10mg nocte	N
10	AD	F	64	10	3.9	22	Donepezil 10mg nocte	N
11	AD	F	64	11	8.1	19	Donepezil 10mg nocte	N
12	AD	F	65	11	4.0	23	Donepezil 10mg nocte	N
13	AD	M	65	13	5.0	25	Donepezil 10mg nocte	N
14	AD	F	66	17	4.5	25	Donepezil 10mg nocte	N
15	AD	M	67	16	11.5	21	Memantine 10mg b.d.	N
16	AD	M	70	18	11.7	28	Donepezil 10mg nocte	N
17	AD	M	71	17	6.3	14	Memantine 10mg b.d.	N
18	AD	F	76	11	8.8	23	none	N
19	AD	F	77	17	4.8	25	Donepezil 5mg nocte	N
20	AD	M	80	9	6.6	22	Donepezil 10mg nocte	N
21	AD	M	76	12	5.9	19	Donepezil 10mg nocte	N
22	PNFA	F	59	16	6.0	14	none	N
23	PNFA	F	66	10	2.8	15	none	N
24	PNFA	F	67	10	4.0	19	none	N
25	PNFA	F	72	17	4.3	26	none	N
26	PNFA	F	77	10	4.3	22	none	N
27	LPA	M	57	14	3.9	11	none	N
28	LPA	M	62	13	2.8	6	Donepezil 10mg nocte	N
29	LPA	M	62	11	3.8	13	Donepezil 10mg nocte	N
30	LPA	M	64	10	4.0	6	Donepezil 10mg nocte	N
31	LPA	F	64	11	3.9	5	none	N
32	LPA	F	69	10	5.8	10	none	N
33	LPA	M	72	10	4.7	15	none	N
34	GAA	M	65	12	3.3	0/29	none	N

		Experimental auditory tests														
Code	Group	Pitch (detection)	Pitch (direction)	Timbre	Size (familiar)	Size (unfamiliar)	Apperceptive	Semantic	Pitch (detection)	Pitch (direction) ¹	Timbre	Size (familiar)	Size (unfamiliar)	Apperceptive	Semantic	
		raw (/20)						raw (/40)			(Z score)					
1	AD	20	20	20	20	18	28	39	0.3	-	0.5	0.2	-1.5	-3.5	0.5	
2	AD	20	20	20	20	20	32	38	0.3	-	0.5	0.2	0.3	-2.0	-0.4	
3	AD	20	20	20	20	20	30	38	0.3	-	0.5	0.2	0.3	-2.8	-0.4	
4	AD	20	20	16	20	20	39	39	0.3	-	-4.5	0.2	0.3	0.7	0.5	
5	AD	15	19	19	19	14	37	34	-12.3	-	-0.8	-1.8	-5.2	-0.1	-4.0	
6	AD	18	18	19	16	20	25	39	-4.8	-	-0.8	-7.8	0.3	-4.7	0.5	
7	AD	20	15	20	17	14	23	33	0.3	-	0.5	-5.8	-5.2	-5.5	-4.9	
8	AD	20	20	20	20	20	33	38	0.3	-	0.5	0.2	0.3	-1.6	-0.4	
9	AD	18	12	14	20	19	27	40	-4.8	-	-7.0	0.2	-0.6	-3.9	1.5	
10	AD	20	20	19	20	20	35	37	0.3	-	-0.8	0.2	0.3	-0.8	-1.3	
11	AD	20	18	20	20	20	37	39	0.3	-	0.5	0.2	0.3	-0.1	0.5	
12	AD	20	20	20	18	16	21	36	0.3	-	0.5	-3.8	-3.4	-6.2	-2.2	
13	AD	17	19	20	20	20	31	37	-7.3	-	0.5	0.2	0.3	-2.4	-1.3	
14	AD	20	20	20	20	20	33	39	0.3	-	0.5	0.2	0.3	-1.6	0.5	
15	AD	20	20	20	20	16	26	40	0.3	-	0.5	0.2	-3.4	-4.3	1.5	
16	AD	20	20	16	17	15	32	36	0.3	-	-4.5	-5.8	-4.3	-2.0	-2.2	
17	AD	20	20	20	20	20	38	40	0.3	-	0.5	0.2	0.3	0.3	1.5	
18	AD	13	17	16	14	8	38	32	-17.3	-	-4.5	-11.8	-10.6	0.3	-5.8	
19	AD	20	20	20	20	20	36	38	0.3	-	0.5	0.2	0.3	-0.5	-0.4	
20	AD	20	20	20	20	20	40	37	0.3	-	0.5	0.2	0.3	1.1	-1.3	
21	AD	18	18	16	20	17	32	31	-4.8	-	-4.5	0.2	-2.5	-2.0	-6.7	
22	PNFA	10	13	12	14	15	29	30	-24.8	-	-9.5	-11.8	-4.3	-3.2	-7.6	
23	PNFA	16	16	11	18	20	39	26	-9.8	-	-10.8	-3.8	0.3	0.7	-11.3	
24	PNFA	20	17	16	20	20	27	35	0.3	-	-4.5	0.2	0.3	-3.9	-3.1	
25	PNFA	20	20	20	20	20	37	35	0.3	-	0.5	0.2	0.3	-0.1	-3.1	
26	PNFA	20	20	19	20	20	39	33	0.3	-	-0.8	0.2	0.3	0.7	-4.9	
27	LPA	18	19	19	12	5	32	30	-4.8	-	-0.8	-15.8	-13.4	-2.0	-7.6	
28	LPA	13	10	11	17		21	29	-17.3	-	-10.8	-5.8	-17.9	-6.2	-8.5	
29	LPA	16	19	16	19	11	25	40	-9.8	-	-4.5	-1.8	-7.9	-4.7	1.5	
30	LPA	20	20	13	11	11	38	28	0.3	-	-8.3	-17.8	-7.9	0.3	-9.5	
31	LPA	19	18	19	20	20	37	36	-2.3	-	-0.8	0.2	0.3	-0.1	-2.2	
32	LPA	11	17	18	20	17	35	35	-22.3	-	-2.0	0.2	-2.5	-0.8	-3.1	
33	LPA	20	20	20	19	19	31	29	0.3	-	0.5	-1.8	-0.6	-2.4	-8.5	
34	GAA	20	18	18	20	20	31	40	0.3	-	-2.0	0.2	0.3	-2.4	1.5	

Code	Group	Regional brain atrophy (see legend)						Peripheral hearing					
		HG	STG	PT	iTL	mTL	Parietal	0.5	1	2	3	4	Unilateral hearing loss
(kHz)													
1	AD			+	+	+	+	N	N	N	N	N	
2	AD			+	+	+	+	N	N	N	N	N	
3	AD			L	L	L	+	N	N	N	N	N	
4	AD			L	L			N	N	N	N	N	
5	AD			+	+	+	+	N	N	N	N	N	
6	AD			L	L		L	+	N	N	N	N	
7	AD			+	+	+	+	+	N	N	AN	N	AN
8	AD			+	+	+	+	N	N	N	N	N	
9	AD			+	+	+	+	N	N	N	N	N	
10	AD						+	N	N	AN	AN	AN	right-sided
11	AD	+	+	+	+	+	+	N	N	N	N	AN	
12	AD	+	+	+	+	+	+	N	N	N	N	N	
13	AD	L	+	L	+	+	+	N	N	N	N	N	
14	AD						+	+	N	N	N	N	
15	AD			+			+	+	N	N	N	N	
16	AD			+	+	+	+	+	N	N	N	N	AN
17	AD	+	+	+	+	+	+	N	N	N	N	N	AN
18	AD			+	+	+	+	+	N	N	N	AN	AN
19	AD	+	+	+	+	+	+	N	N	N	N	N	AN
20	AD	+	+	+	+	+	+	N	N	N	N	N	
21	AD	ns	ns	ns	ns	ns	ns	N	N	N	N	N	
22	PNFA			+	+	+	+	+	N	N	N	N	AN
23	PNFA	L	L	L	L	L	+	N	N	N	N	N	
24	PNFA			+	+	+	+	+	N	N	N	N	N
25	PNFA			+	+	+	+	+	N	N	N	N	N
26	PNFA			+	+	+	+	+	AN	AN	N	AN	AN
27	LPA			L	L	L	L	L	N	N	N	N	N
28	LPA			+	+	+	+	+	N	N	N	N	N
29	LPA			L	L	L	L	AN	AN	AN	N	N	
30	LPA			+	+	+	+	+	N	AN	N	N	AN
31	LPA			L	+	L	+	+	N	N	N	N	N
32	LPA			L	L	L	L	+	N	N	N	N	N
33	LPA			+	+		+	+	N	N	N	AN	N
34	GAA			L	L	L	L	L	N	N	na	na	na

Key	
1	Cannot calculate Z scores due to a lack of variability in the control sample
+	Bilateral atrophy with no strong asymmetry
AD	Alzheimer's disease
AN	Abnormal hearing at indicated frequency level (using normative data from Davis, 1995)
BPVS	British Picture Vocabulary Scale (word-picture naming; Dunn et al., 1982)
GAA	granulin-associated aphasia
HG	Heschl's gyrus
iTL	inferior and middle temporal lobe
L	Bilateral atrophy with more severe damage in the left hemisphere
LPA	Logopenic (phonological) aphasia
mTL	mesial temporal lobe
N	Normal hearing at indicated frequency level (using normative data from Davis, 1995)
na	not administered
ns	no scan
PIQ	performance IQ
PNFA	progressive non-fluent aphasia
PT	planum temporale
RMT	Recognition memory test (Warrington, 1984)
STG	superior temporal gyrus (anterior to HG)
uta	unable to attempt
VIQ	verbal IQ

Legend (Regional brain atrophy)	
All MRI scans were assessed visually by a cognitive neurologist with extensive MRI experience (JW), who was blinded to patients' clinical diagnoses and auditory performance. Six key cerebral regions implicated in auditory processing (Heschl's gyrus, planum temporale, superior temporal gyrus anterior to Heschl's gyrus, inferior temporal lobe, mesial temporal lobe, parietal lobe) were rated as either: unaffected (blank cell); atrophied bilaterally with no strong asymmetry (+); atrophied bilaterally with more severe damage in the left or right hemisphere (L or R).	

Reference	
Davis, A. (1995). Hearing in adults: the prevalence and distribution of hearing impairment and reported hearing disability in the MRC Institute of Hearing Research's National Study of Hearing. London: Whurr Publishers.	